Table 1. Characteristics of the included studies.
| Number of studies | Number of patients | |
|---|---|---|
| Types of cancer | ||
| Ovarian | 14 (26.9%) | 2574 (20.7%) |
| Colorectal | 10 (19.2%) | 3984 (32.0%) |
| Lung | 7 (13.5%) | 2328 (18.7%) |
| Hepatocellular | 5 (9.6%) | 909 (7.3%) |
| Renal cell | 3 (5.8%) | 416 (3.3%) |
| Other | 13 (25.0%) | 2234 (18.0%) |
| Types of lymphocytes a | ||
| CD3+ | 22 (20.0%) | 4678 (37.6%) |
| CD4+ | 15 (13.6%) | 2707 (21.8%) |
| CD8+ | 32 (29.1%) | 9126 (73.3%) |
| FoxP3+ | 23 (20.9%) | 4786 (38.5%) |
| Ratios | 18 (16.3%) | 3017 (24.2%) |
| Type of tissue analysed | ||
| Tissue microarray | 20 (38.5%) | 6487 (52.1%) |
| Whole-tissue slides | 32 (61.5%) | 5958 (47.9%) |
| Areas of scoring | ||
| Hotspots | 15 (28.8%) | 2651 (21.3%) |
| Representative areas | 37 (71.2%) | 9794 (78.7%) |
a
Total percentage is >100%, as most studies included >1 lymphocyte subset, percentage of total numbers of studies and total number of patients included.